Experienced in Hemolytic Transfusion Reaction

Dr. Deepa G. Manwani

Pediatric Hematology Oncology
262 Danny Thomas Pl, 
Memphis, TN 
Clinical Trials:Currently Recruiting for 1 Trial
28 Years of Experience
Experienced in Hemolytic Transfusion Reaction
262 Danny Thomas Pl, 
Memphis, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Deepa Manwani is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Manwani has been practicing medicine for over 28 years and is rated as an Experienced provider by MediFind in the treatment of Hemolytic Transfusion Reaction. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Splenectomy, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 131 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Hemolytic Transfusion Reaction.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN

Locations

262 Danny Thomas Pl, Memphis, TN 38105

Additional Areas of Focus

Dr. Manwani has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase 1-2 Trial of Gamunex (intravenous Gammaglobulin) for Sickle Cell Acute Pain
Phase 1-2 Trial of Gamunex (intravenous Gammaglobulin) for Sickle Cell Acute Pain
Enrollment Status: Recruiting
Publish Date: October 21, 2024
Intervention Type: Drug, Other
Study Drug: Immune Globulin Intravenous
Study Phase: Phase 1/Phase 2
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Enrollment Status: Completed
Publish Date: July 20, 2025
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive Crisis
Enrollment Status: Completed
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients With Iron Overload
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients With Iron Overload
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Deferasirox
Study Phase: Phase 2
Hydroxyurea Adherence for Personal Best in Sickle Cell Disease (HABIT): Efficacy Trial
Hydroxyurea Adherence for Personal Best in Sickle Cell Disease (HABIT): Efficacy Trial
Enrollment Status: Completed
Publish Date: June 26, 2024
Intervention Type: Other, Behavioral
Study Phase: Not Applicable
A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease
A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell Disease
Enrollment Status: Completed
Publish Date: November 21, 2023
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 4
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Phase I/II Study of CaspaCIDe® T Cells From an HLA-Partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders
Enrollment Status: Active_not_recruiting
Publish Date: July 12, 2022
Intervention Type: Biological, Drug
Study Drugs: BPX-501 T Cells, Rimiducid
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

131 Total Publications

Higher aged neutrophils and differential inflammatory profiles in sickle cell disease patients on chronic transfusion therapy versus those on hydroxyurea.
Higher aged neutrophils and differential inflammatory profiles in sickle cell disease patients on chronic transfusion therapy versus those on hydroxyurea.
Journal: Frontiers in immunology
Published: July 22, 2025
Similar Doctors
Advanced in Hemolytic Transfusion Reaction
Dr. Jane S. Hankins
Pediatric Hematology Oncology
Advanced in Hemolytic Transfusion Reaction
Dr. Jane S. Hankins
Pediatric Hematology Oncology
262 Danny Thomas Pl, 
Memphis, TN 
 (0.1 miles away)
901-595-3006
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jane Hankins is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Hankins is rated as an Elite provider by MediFind in the treatment of Hemolytic Transfusion Reaction. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Splenectomy, and Adenoidectomy.

Experienced in Hemolytic Transfusion Reaction
Dr. Ellis J. Neufeld
Pediatric Hematology Oncology
Experienced in Hemolytic Transfusion Reaction
Dr. Ellis J. Neufeld
Pediatric Hematology Oncology
262 Danny Thomas Pl, 
Memphis, TN 
 (0.1 miles away)
901-595-3300
Languages Spoken:
English
See accepted insurances

Ellis Neufeld is a Pediatric Hematologist Oncology provider in Memphis, Tennessee. Dr. Neufeld is rated as a Distinguished provider by MediFind in the treatment of Hemolytic Transfusion Reaction. His top areas of expertise are Blood Clots, Hemophilia A, Thalassemia, Hemolytic Anemia, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Manwani's expertise for a condition
ConditionClose
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile